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Abstract
Background: Mitochondrial presequence proteases perform fundamental functions as they process about 70 % of
all mitochondrial preproteins that are encoded in the nucleus and imported posttranslationally. The mitochondrial
intermediate presequence protease MIP/Oct1, which carries out precursor processing, has not yet been established
to have a role in human disease.
Methods: Whole exome sequencing was performed on four unrelated probands with left ventricular non-compaction
(LVNC), developmental delay (DD), seizures, and severe hypotonia. Proposed pathogenic variants were confirmed by
Sanger sequencing or array comparative genomic hybridization. Functional analysis of the identified MIP variants was
performed using the model organism Saccharomyces cerevisiae as the protein and its functions are highly conserved
from yeast to human.
Results: Biallelic single nucleotide variants (SNVs) or copy number variants (CNVs) in MIPEP, which encodes MIP, were
present in all four probands, three of whom had infantile/childhood death. Two patients had compound heterozygous
SNVs (p.L582R/p.L71Q and p.E602*/p.L306F) and one patient from a consanguineous family had a homozygous SNV (p.
K343E). The fourth patient, identified through the GeneMatcher tool, a part of the Matchmaker Exchange Project, was
found to have inherited a paternal SNV (p.H512D) and a maternal CNV (1.4-Mb deletion of 13q12.12) that includes MIPEP.
All amino acids affected in the patients’ missense variants are highly conserved from yeast to human and
therefore S. cerevisiae was employed for functional analysis (for p.L71Q, p.L306F, and p.K343E). The mutations p.
L339F (human p.L306F) and p.K376E (human p.K343E) resulted in a severe decrease of Oct1 protease activity
and accumulation of non-processed Oct1 substrates and consequently impaired viability under respiratory
growth conditions. The p.L83Q (human p.L71Q) failed to localize to the mitochondria.
Conclusions: Our findings reveal for the first time the role of the mitochondrial intermediate peptidase in
human disease. Loss of MIP function results in a syndrome which consists of LVNC, DD, seizures, hypotonia,
and cataracts. Our approach highlights the power of data exchange and the importance of an interrelationship
between clinical and research efforts for disease gene discovery.
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Background
Left ventricular non-compaction (LVNC) is a heteroge-
neous disorder that may present with heart failure,
arrhythmia, and systemic embolism [1]. Failure to develop
compact myocardium in the early embryo results in
LVNC with the underlying genetic basis identified in
around 30–50 % of individuals with LVNC [1]. Different
modes of inheritance have been described for LVNC, in-
cluding autosomal dominant, X-linked, and mitochondrial
inheritance. Among them, the most prevalent form is the
autosomal dominant inheritance pattern (70 % of all cases
where the genetic basis is known) with incomplete pene-
trance [1, 2].
Mechanisms that have been implicated in LVNC include
variants in genes encoding the substructures of the sarco-
mere in cardiomyocytes. For example, variants in MYH7
(MIM 613426) and MYBPC3 (MIM 615396) both lead to
a disruption of myosin function [3, 4]. Additionally, vari-
ants in ACTC1 (MIM 613424), TNNT2 (MIM 601494),
TPM1 (MIM 611878) and DTNA (MIM 604169) cause
dysfunction of actin, troponin, tropomyosin, and dystro-
brevin, respectively [4–7]. Moreover, variants in LDB3
(MIM 601493), a gene that plays a role in the maintenance
of structural integrity of cardiomyocytes, has been associ-
ated with LVNC [8]. Recently, variants in MIB1 (MIM
615092) have been identified to cause abnormal cardiac
trabeculations through dysregulation of the NOTCH
pathway [9]. Furthermore, truncations and missense vari-
ants of TAZ (MIM 302060), a mitochondrial transacylase,
have been associated with X-linked dominant LVNC in
male patients with Barth syndrome [7, 10]. In many cases
of LVNC, however, the underlying genetic bases remain
unknown.
We have identified several single nucleotide variants
(SNVs) in MIPEP in patients with LVNC. Using whole ex-
ome sequencing (WES), a homozygous missense SNV in
MIPEP was identified in a child from a consanguineous
family, two compound heterozygous SNVs were found in
individuals from two unrelated, non-consanguineous fam-
ilies, and a paternally inherited SNV and maternally inher-
ited 1.4-Mb deletion copy number variant (CNV) was
found in a fourth child. Although the aforementioned
searches were based upon finding damaging variants in the
same gene, remarkably the predominant clinical features
shared by all four subjects included LVNC, developmental
delay (DD), seizures, and hypotonia; three experienced in-
fantile/early childhood death secondary to cardiomyopathy.
MIPEP encodes the mitochondrial intermediate pep-
tidase (MIP in human, Oct1 in yeast) [11–13]. A vast
majority of mitochondrial proteins are encoded by the
nuclear DNA. These mitochondrial preproteins are then
translated on cytosolic ribosomes and imported post-
translationally. Approximately 70 % of these preproteins
use N-terminal targeting signals (presequences) for import
and translocation across the mitochondrial membranes
[14]. Upon entry into the mitochondrial matrix these
presequences are cleaved by specialized proteases, the
mitochondrial presequence proteases. The major part
of the presequence is cleaved by the mitochondrial pro-
cessing peptidase (MPP). However, approximately one
quarter of preproteins require a secondary processing that
is carried out by the mitochondrial intermediate peptidase
MIP/Oct1 or mitochondrial X-prolyl aminopeptidase 3
(XPNPEP3), also known as intermediate cleaving peptid-
ase Icp55 in yeast and plants [13–16]. MIP/Oct1 removes
an additional octapeptide after MPP cleavage (Fig. 1),
while XPNPEP3/Icp55 removes a single amino acid [16].
All proteases involved in presequence cleavage are highly
conserved from yeast to human, evidence of their funda-
mental role in mitochondrial biogenesis.
MIPEP (MIM 602241, NM_005932) [17, 18] is comprised
of 19 exons and maps to chromosome 13q12.12 [19]. MIP
is expressed at high levels in heart, brain, skeletal muscle,
and pancreas, all tissues that require a significant amount
of energy and therefore are dependent on efficient mito-
chondrial ATP production [19–21]. Furthermore, these
tissues are often affected in individuals with various mito-
chondrial disorders, including MELAS (MIM 540000)
and Pearson marrow-pancreas syndrome (MIM
557000) [22, 23]. A broad range of cardiomyopathy
disorders have been linked to mitochondrial dysfunc-
tion [21, 24, 25]. Here, we report a clinical syndrome
of LVNC, DD, seizures, hypotonia, cataracts, and in-
fantile death associated with MIPEP dysfunction.
Methods
Sequencing
The first three patients initially had clinical WES per-
formed in the Whole Genome Laboratory (WGL), a part
of Baylor Genetics Laboratories at Baylor College of
Medicine [26]. The coding exons of approximately
20,000 genes were targeted by WES [26, 27] with 130×
average depth-of-coverage and >95 % of the targeted
bases with >20 reads. The post-processing of raw
sequence data was performed using the Mercury pipe-
line [28]. First, the raw sequencing data (bcl files) were
converted to fastq files using Casava. Next, mapping of
short reads to the human genome reference sequence
(GRCh37) was performed by the Burrows-Wheeler
Alignment (BWA) tool. Recalibration and variant calling
were then performed using GATK [29] and the Atlas2
suite, respectively [30]. The Mercury pipeline is available
in the cloud via DNANexus (http://blog.dnanexus.com/
2013-10-22-run-mercury-variant-calling-pipeline/). Any
individuals or families in whom clinical WES did not
identify a molecular diagnosis in known human dis-
ease genes were contacted for possible enrollment in
the Baylor-Hopkins Center for Mendelian Genomics
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(BHCMG) Project for further research analysis of
WES data and/or WES of additional family members.
The first patient enrolled in the BHCMG Project had
MIPEP prioritized as a potential candidate gene based
on the clinical impression of a mitochondrial dis-
order. Upon further communication with the clinical
exome laboratory, two additional individuals with
biallelic variants in MIPEP were identified and found
clinically to have been referred with a diagnosis of
LVNC cardiomyopathy (although the phenotype was
not a criteria for the search). The study was approved
by the institutional review board (IRB) of Baylor Col-
lege of Medicine. Additionally, we Sanger sequenced
MIPEP in 11 individuals aged younger than 5 years
with cardiomyopathy and unknown molecular diagno-
ses at the Baylor Genetics Laboratory.
Experimental methods
Yeast strains and growth conditions
The Saccharomyces cerevisiae strains used in this study
are derived from BY4741 oct1Δ (Mata; his3Δ1; leu2Δ0;
met15Δ0; ura3Δ0; YKL134c::kanMX4) and YPH499
(MATa, ade2-101, his3-Δ200, leu2-Δ1, ura3-52, trp1-
Δ63, lys2-801). For re-expression of Oct1 in the oct1Δ
strain, the open reading frame under its endogenous pro-
moter and terminator region was cloned into the pRS413
expression vector [12]. Mutations were introduced using
site-directed mutagenesis. All plasmids were sequenced
and subjected to in vitro transcription/translation in the
presence of [35S]methionine and analyzed by SDS-PAGE/
autoradiography as quality control. The obtained strains
were grown on minimal medium (6.7 % (w/v) yeast nitro-
gen base without amino acids, 2 % glucose (w/v), 0.77 %
Complete Supplement Mixture minus histidine).
Mutant generation by plasmid shuffling
To enable analysis of mutations in vivo under respiratory
conditions, the Oct1 protein was expressed from the
pRS416 plasmid (ura3). Subsequently, the genomic copy
of OCT1 was deleted by homologous recombination.
The strain was then transformed with a plasmid encod-
ing Oct1 (pRS413_Oct1) or Oct1 with point mutations
resulting in the following amino acid exchanges: L83Q,
L339F, K376E, N575D, L645R, and N666* (Additional
file 1: Figure S1). All OCT1 variants were expressed
under the endogenous OCT1 promoter and terminator
regions and carried a C-terminal HA tag. When the cells
are grown on 5-fluoroorotic acid (5-FOA), the ura3 gene
product converts the 5-FOA into a toxic compound and
the cells are selected for pRS416 plasmid loss (plasmid
shuffling). Transformation with pRS413_Oct1N575D,
pRS413_Oct1L645R and pRS413_Oct1N666* did not result
Fig. 1 Import of nuclear-encoded proteins into mitochondria and their processing. This process is guided by N-terminal presequences that direct
import across the mitochondrial outer and inner membranes through translocons. Precursor processing by MPP and MIP/Oct1 removes the presequence
and an additional octapeptide resulting in the mature, stable protein
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in viable yeast cells. Of the obtained yeast strains ex-
pressing Oct1 mutants L83Q, L339F, and K376E, five in-
dependent clones of each mutant and four independent
clones of the wild type (OctWT) were tested for growth
defects. All clones analyzed showed the same growth be-
havior. Two to three clones were selected and mitochon-
dria isolated, all of which showed the accumulation of
processing intermediates of Oct1 substrates.
For growth tests yeast cells were grown overnight in
5 ml YPG medium at 24 °C. Cell numbers (OD600) were
measured and adjusted and tenfold serial dilutions were
spotted on YPD and YPG agar plates. Plates were incu-
bated at the indicated temperatures.
Isolation of mitochondria
For isolation of mitochondria, cells were grown at 24 °C on
fermentable medium (1 % (w/v) yeast extract, 2 % (w/v)
bacto peptone, 2 % (w/v) sucrose, pH 5.0) or non-
fermentable medium (3 % (w/v) glycerol instead of sucrose).
Strains expressing the mutant Oct1 proteins (L339F,
K376E) were shifted for 10 h to 37 °C prior to isolation of
mitochondria. Cells were harvested in the logarithmic
growth phase (OD600 1.0–1.5) and mitochondria isolated
by differential centrifugation as described previously [31].
Aliquots were stored in SEM buffer (250 mM sucrose,
1 mM EDTA, 10 mMMOPS-KOH, pH 7.2) at −80 °C. Pro-
tein levels were analyzed by SDS-PAGE and immunode-
coration according to standard protocols.
In organello import and processing of Oct1 substrate
proteins
Radiolabeled precursor proteins were generated by in
vitro transcription/translation in rabbit reticulocyte ly-
sates (Promega) in the presence of [35S]methionine and
incubated with 50 μg isolated mitochondria for the indi-
cated time periods in import buffer (10 mM MOPS/
KOH, pH 7.2, 3 % (w/v) bovine serum albumin, 250 mM
sucrose, 5 mM MgCl2, 80 mM KCL, 5 mM KPi, 2 mM
ATP, and 2 mM NADH) [31]. As a control for specific
import into mitochondria, membrane potential (Δψ) was
dissipated prior to the import reaction by the addition of
1 μM valinomycin, 20 μM oligomycin, and 8 μM antimy-
cin A (supplied as AVO mix (1 % (v/v)). All reactions were
stopped by addition of 1 % (v/v) AVO. Samples were then
placed on ice and treated with 50 μg/ml proteinase K for
10 min. After addition of 2 mM PMSF (phenylmethylsul-
fonyl fluoride) mitochondria were washed with SEM buf-
fer and subjected to SDS-PAGE [31]. Imported and
processed precursor proteins were monitored by digital
autoradiography of vacuum-dried electrophoresis gels. All
import experiments were reproduced at least two times
and with at least two independent cell clones.
Results
Genomic analysis
WES data from patient 1 was transferred to BHCMG
and re-analyzed for SNVs in genes not presently associ-
ated with human disease in an attempt to determine
the molecular underpinnings of the phenotype. Poten-
tially pathogenic compound heterozygous variants
(p.L582R/p.L71Q) were identified in MIPEP; given what
is known about the biology of MIP, this was further
pursued as the best potential candidate gene. No other
candidate genes with variants bioinformatically pre-
dicted to be damaging and conveying a similarly match-
ing phenotype were identified. Upon exchange of our
data with the clinical exome laboratory, we identified
two more patients with variants in MIPEP who both
coincidentally had a similar phenotype; patient 2 was
found to have compound heterozygous variants
(p.E602*/p.L306F) and patient 3 had a homozygous
variant (p.K343E). We next submitted MIPEP to the
GeneMatcher tool, a part of the Matchmaker Exchange
project (https://genematcher.org) [32, 33], and success-
fully matched one other patient with a paternally inher-
ited MIPEP SNV (p.H512D) and maternally inherited
1.4-Mb deletion copy number variant (CNV) encom-
passing the entire gene. Sanger sequencing in the pro-
bands and family members confirmed the variants’
presence and their biallelic nature in the probands
(Fig. 2). Due to the lack of availability of parental DNA
for patient 3, Sanger sequencing of the homozygous
variant (p.K343E) was followed by digital droplet PCR
to confirm that the variant was indeed homozygous
(Additional file 2: Figure S2).
In total, we identified four individuals from four unre-
lated families with one homozygous and three com-
pound heterozygous variants in MIPEP ( 1). Given that
patient 1 with LVNC and cardiomyopathy was initially
suspected to have a mitochondrial disorder, MIPEP was
prioritized to be an excellent candidate gene given its
fundamental role in mitochondrial biogenesis. MIPEP is
the strongest candidate among screened variants
because the nonsynonymous variants in MIPEP are evo-
lutionarily conserved (Fig. 2) and predicted to be dele-
terious by Mutation Taster, SIFT, PolyPhen2, and CADD
(Table 1). Additionally, in our internal Baylor-CMG re-
search database with ~5000 patients, we did not identify
any homozygous or compound heterozygous variants in
MIPEP in subjects who presented with other pheno-
types. We also searched our clinical exome laboratory
database, which also included ~5000 clinical exomes,
and did not find any other individuals with homozygous
and compound heterozygous MIPEP variants. Upon
examination of the 1000 Genome Project, exome variant
server (of the Exome Sequencing Project), and Exome
Aggregation Consortium (ExAC) databases, we observed
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that four out of six variants (p.L582R, p.L71Q, p.E602*,
and p.K343E) are novel and two variants (p.L306F and
p.H512D) are rare, observed in the ExAC database in
the heterozygous state at a frequency of 8.2 × 10−6 and
3.2 × 10−5, respectively. The heterozygous maternal dele-
tion of patient 4 was identified by array comparative
genomic hybridization (Affymetrix CytoScan® HD) and
encompasses 1.4 Mb at 13q12 (chr13: 23,519,916–
24,941,516, hg19) (Fig. 2; Additional file 3: Figure S3).
Clinical spectrum
Retrospective clinical analyses delineated a consistent
phenotype of cardiomyopathy, LVNC, seizures, and hypo-
tonia/developmental delay in all subjects with infantile or
early childhood death. Patient 1 was born full term by
vaginal delivery after an uncomplicated pregnancy. By
5 months of age, he presented with failure to thrive. At
5.5 months of age, he was diagnosed with LVNC and ECG
showed Wolf–Parkinson–White (WPW) syndrome. His
family history is notable for a paternal uncle with a history
of supra-ventricular tachycardia and maternal great-aunt
with early myocardial infarction (29 years of age) but was
otherwise unremarkable. His father’s family is of Scottish/
Mexican/Native American ancestry and mother’s family is
of Colombian/Native American ancestry. There is no
known consanguinity. Physical examination revealed
length, weight, and head circumference below the fifth
centile and he had a wide mouth and bulbous nasal tip,
demonstrated tongue-thrusting, and was hypotonic with
head lag. Brain MRI showed microcephaly with prominent
extra-axial cerebrospinal fluid (CSF) spaces. Evaluations
revealed an anion gap metabolic acidosis (anion gap = 25;
reference range 3–11 mEq/L) with lactate of 3.2 mmol/L
(reference range 0.7–2.1 mmol/L). Plasma amino acid
analysis revealed slightly elevated alanine of 553 μmol/L
(reference range 103–528 μmol/L) but was otherwise un-
remarkable. Skeletal muscle biopsy showed evidence for
mitochondrial proliferation and lipid droplets by electron
microscopy (Table 1). Electron transport chain (ETC) ana-
lysis of muscle at a CLIA-certified laboratory showed re-
ductions in several respiratory chain complex activities,
although not sufficiently low to satisfy a minor criterion of
Fig. 2 a Pedigree structure and segregation analysis for MIPEP variants in four families. b Evolutionary conservation of MIPEP variants among
different species at the variant positions found in the study subjects
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Table 1 MIPEP variants in four unrelated patients from four unrelated families
Patient ID P1 P2 P3 P4
Zygosity Compound heterozygous Compound heterozygous Homozygous Compound heterozygous
Nucleotide change(s) c.1745 T > G; c.212 T > A c.916C > T; c.1804G > T c.1027A > G c.1534C > G; NA
Protein change(s) p.L582R; p.L71Q p.L306F; p.E602* p.K343E p.H512D; NA
db SNP ID(s) NA rs143912947, NA NA NA
ExAC frequency NA 8.2 × 10−6, NA NA 3.2 × 10−5, NA
Mutation Taster D D D D, NA
SIFT D D D D
PolyPhen-2 0.99, 1.00 0.98, NA 0.97 1.00, NA
CADD 1.0 (Phred-like) 29.9, 28.0 29.5, 48 28.5 33, NA
Metabolic myopathy
features
Examination of skeletal muscle showed:
1. Moderate variation in fiber size with type 1
fiber predominance
2. Many fibers with increase in subsarcolemmal
oxidative activity
3. Increased mitochondria in many fibers by
trichrome stain
4. Marked mitochondrial proliferation and
pleomorphism on electron microscopy
5. Marked increase in lipid droplets on electron
microscopy
Examination of quadriceps muscle by light
microscopy showed:
1. Mild variation in fiber size; type 1 fiber
predominance with type 1 to type 2
fiber ratio of 70:30
2. Diffuse, moderate to marked increase in
glycogen stores on PAS special stain
Electron microscopy showed: membrane-bound
glycogen deposits; diffuse, mild to moderate
increase in lipid droplets on oil-red-O special
stain and no increase in oxidative enzyme
staining; no increase in mitochondria or mitochondrial
pleomorphism, no evidence for a dystrophic process
NA Light and electron microscopic findings of the
skeletal muscle (diaphragm) and cardiac muscle
showed:
1. Numerous lipid droplets, glycogen deposition
(especially cardiac muscle), and large aggregates
of mitochondria.
2. In the skeletal myofibers, the aggregates of
mitochondria were often adjacent to vessels.
Many of the mitochondria were quite enlarged
and had bloated vesicular cristae
3. The ventricles showed thick trabeculae that
spanned the lumen and focal clefts in their thick
walls. The myofibers swirled and interlaced
together. A few, scattered nuclei were enlarged
and box-car shaped. Cross striations were
well-preserved
CADD (Phred-like) scores ≥20 indicate the variants are among the top 1 % of the most deleterious variants in the genome
D damaging, NA not applicable, PAS periodic acid–Schiff
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the modified Walker criteria for the diagnosis of a respira-
tory chain disorder (Additional file 4: Table S1) [34]. His
hypotonia evolved into hypertonia and he has continuous
abnormal movements and dystonic posturing. His EEG
was normal. He also developed multiple gastrointestinal
symptoms, including intermittent vomiting and constipa-
tion. He is alive at 4.5 years of age.
Patient 2 was a product of full-term gestation and
pregnancy was uncomplicated. A cataract was noted in
the left eye shortly after birth and was removed at
3 months of age. She was irritable and fed poorly in the
first months of life and had an upper endoscopy at
9 months of age that revealed eosinophilic esophagitis.
At 11 months of age she presented with poor feeding
and fatigue and was diagnosed with LVNC and dilated
cardiomyopathy. Family history was significant for an
older brother who had cataracts and infantile spasms
and died unexpectedly at 14 months of age of unknown
cause. Parents are of European ancestry with no known
consanguinity. On physical exam, she had significant
hypotonia and global developmental delay. Clinical test-
ing for mitochondrial and other genetic disorders was
performed throughout her lifetime and failed to identify
a cause for LVNC and hypotonia. She was listed for
heart transplant and had a Berlin assist device inserted
as a bridge to transplant after worsening cardiac ejection
fraction. She subsequently developed uncontrollable
seizures. The Berlin device was removed and she died at
the age of 2 years. An autopsy revealed diffuse neuronal
loss with parenchymal rarefaction and cortical/white
matter gliosis involving the frontal cortex, ventral fore-
brain, and pontine tegmentum (likely secondary to poor
brain perfusion from heart disease). LVNC with dilated
cardiomyopathy was noted and quadriceps muscle bi-
opsy revealed features of metabolic myopathy (Table 1).
Patient 3 was born at 36 weeks gestation due to pre-
term labor. The pregnancy had been uncomplicated.
The parents are first-degree cousins from Egypt. There
are no similar medical problems in the family. At the
age of 2.5 months he had feeding problems with failure
to thrive. He was not focusing and exhibited no social
smile. At the ages of 5 and 10 months, he was admitted
to the hospital for respiratory problems, metabolic acid-
osis (with lactates of 4.4 and 11.1, respectively; reference
range 0.7–2.1 mmol/L) and transient elevation in liver
enzymes (alanine transaminase (ALT) 357 U/L, aspartate
transaminase (AST) 428 U/L; reference range ALT 6–45
U/L, AST 20–60 U/L). At the age of 9 months, echocar-
diogram revealed left ventricular hypertrophy without
left ventricular outflow tract obstruction and a small
secundum atrial septal defect with left to right shunt.
The biventricular function was normal. On physical
examination, he was noted to have a long philtrum.
There was opisthotonus and severe head lag when pulled
to sit. By the age of 10 months he developed microceph-
aly and seizures. Clinical mitochondrial ETC studies
from skin biopsy showed mild reductions in all mito-
chondrial complexes except for complex II and complex
V, which were normal (Additional file 4: Table S1). On
brain MRI at 10 months, diffusion-weighted images
showed a bilateral and symmetrical increase in signal in-
tensity of the basal ganglia, involving mainly the lenti-
form nucleus. The periventricular white matter showed
hyperintense signal in T2-weighted images, interpreted
as either normal myelination processes or changes
reflecting neurodegenerative processes or a metabolic
disorder. The spectroscopy sample on the basal ganglia
showed signs of neuronal loss or degradation. He died at
11 months of age.
Patient 4 was delivered by Cesarean section at
33 weeks gestation due to maternal preeclampsia and
fetal decelerations. At birth, he was noted to have sig-
nificant respiratory depression and was intubated. Sei-
zures began within the first hour of life. Physical
examination revealed a gallop rhythm and an echo-
cardiogram demonstrated severe biventricular hyper-
trophic cardiomyopathy. He had dysmorphic features
including deep-set eyes, anteverted nares, depressed
nasal bridge, midface hypoplasia, severe micrognathia,
facial asymmetry, and an accessory palmar crease on
the right hand. He was diagnosed with congenital
hyperinsulinemia (blood glucose 20 mg/dL; reference
range 70–110 mg/dL) and lactic acidosis (8.9–
10.4 mmol/L; reference range 0.7–2.1 mmol/L). La-
boratory studies showed significant elevations in ala-
nine, glutamine, and proline that were likely to be
consistent with liver disease and lactic acidemia.
Urine organic acid analysis showed elevated lactate,
pyruvate, ketones, and intermediates of the Krebs
cycle consistent with lactic acidosis and ketosis. On
day 8 of life he was diagnosed with microcolon. By
day 14 of life, he required increased ventilatory sup-
port; despite this, blood gases continued to worsen
with a persistent lactic acidosis and on day 19 of life
he expired. Autopsy demonstrated multiple anomalies
including rhombencephalosynapsis, narrow bowel, di-
lated urinary bladder and ureters, small lungs, and
massive thick-walled heart. The ventricles showed
thick trabeculae that spanned the lumen and thick
walls with underlying non-compaction and focal
clefts. Additional cardiac findings included patent
ductus arteriosus, small membranous ventricular sep-
tal defect, congestive heart failure, and pericardial
edema. Light and electron microscopic findings of
skeletal muscle (diaphragm) and cardiac muscle
showed numerous lipid droplets, glycogen deposition
(especially cardiac muscle), and large aggregates of
mitochondria with bloated vesicular cristae (Table 1).
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Family history is significant for a previous female
infant that presented with cardiomyopathy in the im-
mediate postnatal period and subsequently expired by
16 days of life; it is unknown if she had LVNC or
other features such as hypotonia and cataracts.
Functional analyses
MIP and its yeast homologue Oct1 are highly conserved
(Additional file 1: Figure S1). Therefore, we employed a
yeast model system to assess the effects of the disease
mutations on MIP in vivo. We introduced the Oct1 mu-
tations by site-directed mutagenesis and expressed the
wild type and disease mutants from a plasmid under the
endogenous promoter in an OCT1 deletion strain [12].
Mitochondria were isolated and analyzed for Oct1 pro-
cessing defects by SDS-PAGE and immunodecoration
(Fig. 3a). Re-expression of the wild-type Oct1 protein
rescued the processing defect of the Oct1 substrates
Mdh1 and Sdh4 (Fig. 3a, lanes 1 and 4) while yeast cells
transformed with the empty vector (e.v.) as control
showed complete accumulation of Oct1 processing in-
termediates (Fig. 3a, lanes 2 and 5). Mutation of Oct1 at
position L83Q (MIP L71Q) also fully abolished Oct1
processing (Fig. 3a, lane 3). Immunodecoration using an
antibody specific to Oct1 revealed that expression of the
L83Q mutant does not result in detectable Oct1 protein
levels in mitochondria. Consequently, the L83Q mu-
tant mimics an OCT1 deletion phenotype. Mutations
of L339F (MIP L306F, Fig. 3a, lane 6) and K376E
(MIP K343E, Fig. 3a, lane 7) showed increased accu-
mulation of Oct1 processing intermediates for Mdh1
and Sdh4, indicating an impaired Oct1 proteolytic
function in these mutants in vivo. In contrast, non-
Oct1 substrates (controls) were not changed and the
protein levels of these two Oct1 mutants were com-
parable to those of the wild type.
Deletion of Oct1 in yeast results in loss of mitochon-
drial DNA. As a consequence OCT1 deletion strains are
not viable on non-fermentable carbon sources (where
mitochondrial respiration is essential for cell viability).
Several of the known Oct1 substrates, e.g., Rip1 and
Cox4, are subunits of the respiratory chain complexes or
the mitochondrial ribosome, e.g., Mrp21, and are, there-
fore, required for survival under respiratory growth con-
ditions. In order to analyze the effect of the Oct1
mutants under respiratory conditions, we generated
yeast cells expressing the various Oct1 mutants by plas-
mid shuffling (see “Methods” for details). The approach
yielded viable strains for the L83Q, L339F, and K376E
Oct1 mutants. (However, due to the lack of Oct1 in the
Fig. 3 In vivo analysis of MIPEP-derived SNVs in the homologous Oct1 protein from S. cerevisiae. a Immunoblot analysis of mitochondria isolated
from oct1Δ yeast cells transformed with plasmids encoding wild-type Oct1 (Oct1WT) or Oct1 mutants (L83Q, L339F, K376E) under the endogenous
promoter or the empty control plasmid (e.v.). Cells were grown at 24 °C on a fermentable carbon source prior to organelle isolation. b Growth of
yeast strains expressing Oct1WT or mutants Oct1L339F and Oct1K376E. Plasmid shuffling generated strains and growth behavior assessed on fermen-
tative and respiratory carbon sources at low (23 °C) and high (37–38 °C) temperature. c Immunodecoration of mitochondria isolated from strains
shown in b after cell growth for 10 h at 37 °C under respiratory conditions (non-fermentable carbon source). i processing intermediate, m mature
protein, p precursor
Eldomery et al. Genome Medicine  (2016) 8:106 Page 8 of 13
mitochondria of the L83Q strain, growth under respira-
tory growth assessment was not possible.) While both
Oct1 L339F and K376E expressing strains showed no
growth defect on fermentative carbon sources, both
strains displayed a severe growth defect under respiratory
conditions at higher temperature (Fig. 3b). We isolated
mitochondria from these strains after growth at a non-
permissive temperature for 10 h and analyzed the protein
steady state levels by SDS-PAGE and immunodecoration
(Fig. 3c). In both mutants we found strong accumulation
of the processing intermediates of Mdh1, Sdh4, Cox4,
Mdj1, Prx1, and Rip1, revealing a severe decrease of Oct1
activity. The processing defect was most pronounced in
the K376E mutant, in which the mature form of Rip1 was
virtually absent. Control proteins, which are not substrates
of Oct1, were not affected. Taken together, the analyses of
the Oct1 mutations in vivo under respiratory conditions
demonstrate a strong accumulation of processing interme-
diates of Oct1 substrates inside mitochondria, indicating a
decreased proteolytic activity of Oct1.
In order to directly analyze Oct1 activity in the mutant
strains in vitro, we generated [35S]radiolabeled precursor
proteins of the Oct1 substrates Mdh1, Cox4, and Mrp21
by in vitro transcription/translation and imported them
into isolated mitochondria. Samples were separated via
SDS-PAGE and the different precursor processing steps
were monitored by autoradiography [12, 31]. For all
three precursor proteins the Oct1-mediated processing
of the intermediate (i) forms to the mature (m) protein
was severely impaired (Fig. 4a-c). Strikingly, the more af-
fected Oct1 processing activity in the K376E mutant
mitochondria correlated with the stronger accumulation
of precursor intermediates in the mutant cells in vivo
(Fig. 3c). Processing of the Atp2 precursor, which is
cleaved by MPP but not Oct1, was not affected (Fig. 4d).
Thus, our approach revealed that both mutations L339F
and K376E diminish the proteolytic activity of Oct1 not
only in vivo but also in a direct in organello processing
assay.
Discussion
The application of WES in clinical practice has led to the
identification of novel Mendelian disorders [26, 35, 36].
We have identified four individuals with rare biallelic vari-
ants in MIPEP who presented with a syndrome of LVNC,
DD, seizures, hypotonia, cataracts, and infantile death.
Three out of four patients (75 %) have passed away in the
first 3 years of life. This demonstrates the association be-
tween pathogenic biallelic variants in MIPEP and LVNC
and early childhood death [37].
Mitochondrial presequence proteases are essential to
maintain a functional mitochondrion. The majority of
imported mitochondrial preproteins carry N-terminal
presequences as targeting signals and require proteolytic
cleavage by presequence proteases. While some mito-
chondrial proteins only require one step of presequence
cleavage by MPP, approximately 25 % of proteins with the
N-terminal targeting sequence require a second step of
cleavage by MIP or XPNPEP3/Icp55. In this 25 %, the
MPP processing intermediates carry destabilizing N-
terminal amino acids and are subject to rapid degradation
[12, 14, 15]; removal of an additional octapeptide by Oct1
or a single amino acid by XPNPEP3/Icp55 reveals stabiliz-
ing N-terminal residues following a mitochondrial N-end
rule [12, 14, 16, 38]. The proteolytic action of Oct1 and
XPNPEP3/Icp55 is required, therefore, to maintain a
stable mitochondrial proteome (Fig. 1).
Functional analysis of the Oct1 L306F/L339F and
K343E/K376E mutants revealed a severe decrease in Oct1
processing activity, as demonstrated by accumulation of
processing intermediates. These processing intermediates
included subunits of ETC complexes Sdh4 (succinate de-
hydrogenase, subunit of respiratory chain complex II and
a novel Oct1 substrate), Rip1 (Rieske iron-sulfur-protein,
subunit of respiratory chain complex III), Cox4 (cyto-
chrome c oxidase, subunit 4 of respiratory chain complex
IV), the citrate cycle enzyme Mdh1 (mitochondrial malate
dehydrogenase), the ribosomal subunit Mrp21, the perox-
iredoxin Prx1, and the mtHsp70 co-chaperone Mdj1 (also
a novel Oct1 substrate) (Figs. 3 and 4), which showed
strong accumulation in strains expressing the mutant ver-
sions of Oct1 (L339F and K376E). Since most of these
proteins either directly or indirectly influence mitochon-
drial respiratory chain activity, it is highly likely that MIP/
Oct1 defects affect mitochondrial bioenergetics. There-
fore, defects in Oct1 activity might impact on respiratory
chain activity.
Analysis of the protein levels of the Oct1 mutant
L83Q revealed that the protein was not detectable in
isolated mitochondria; the Oct1 L83Q mutant consist-
ently mimicked an OCT1 deletion phenotype (Fig. 3).
This could be caused by decreased import rates or rapid
turnover of the mutant protein upon synthesis or trans-
location into mitochondria.
Our functional data are analogous to the previous ex-
periments in yeast illuminating the consequences of loss
of Oct1 activity. Previously it has been demonstrated that
the deletion of the yeast homolog of MIPEP, Oct1, dis-
rupted iron-sulfur (FeS), Cox4, and ornithine transcarba-
moylase (OTC) protein maturation. Conversely, the
reintroduction of Oct1 into the yeast led to the resump-
tion of FeS, Cox4, and OTC protein processing [39]. Fur-
thermore, the biochemical and metabolic consequences of
Oct1 deletion include a significant reduction in NADH
dehydrogenase activity and succinate dehydrogenase activ-
ity that has been explained by a partial loss of mitochon-
drial respiratory component function [39]. Subsequent
experiments in a yeast experimental model revealed other
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functions of Oct1, including its role in processing of mito-
chondrial proteins involved in regulation of mtDNA repli-
cation [39, 40]. The biochemical evaluations of Oct1 in
yeast have shed light on its protein structure, revealing a
zinc-binding domain involved in its cleavage activity. Mu-
tations in the zinc-binding domain disrupt the Oct1 cata-
lytic activity; four mutations in the zinc-binding domain,
including p.H558R, p.E559D, p.H565R, and p.E587D,
caused global loss of Oct1 activity in yeast [41].
Recessive mutations in XPNPEP3 (MIM 613159) have
been reported to cause nephronophthisis-like nephropa-
thy 1 (NPHPL1) [42]. Mutations in the alpha subunit of
MPP, encoded by PMPCA (MIM 213200), have been
recently identified to cause an autosomal recessive form
of non-progressive cerebellar ataxia [43]. Copy number
variations and SNVs have been reported to alter the
inner mitochondrial membrane peptidase subunit 2
encoded by IMMP2L, causing neurodevelopmental
Fig. 4 In organello processing activity of Oct1L339F and Oct1K376E mutants. a–c In vitro import and processing of radiolabeled Mdh1, Cox4, and
Mrp21 preproteins in isolated mitochondria (Mito.) from indicated mutant strains compared to wild type (Oct1WT). d In vitro import and processing of
the Oct1-independent preprotein Atp2. The reaction was performed as in a–c. Δψ is the mitochondrial membrane potential. i processing intermediate,
m mature protein, p precursor
Eldomery et al. Genome Medicine  (2016) 8:106 Page 10 of 13
disorders and age-associated neurodegeneration, respect-
ively [44, 45]. Our identification of pathogenic variants
in MIPEP in patients with LVNC and neurologic abnor-
malities illustrates the fundamental role of presequence
proteases in mitochondrial protein processing and func-
tion and their contribution to human disease.
Conclusions
Our study reveals the first link between SNVs in the gene
of the mitochondrial intermediate peptidase MIPEP and
severe forms of LVNC. Phenotypic evaluation following
the identification of biallelic MIPEP variants in four pa-
tients identified a shared and rare syndrome of LVNC,
DD, seizures, hypotonia, cataracts, and infantile/early
childhood death. Experimental data in yeast support the
pathogenicity of these variants and indicates that the
mechanism of action is loss of function of MIP. The iden-
tification and description of the patients’ genotype and
phenotype together with functional biochemical analysis
provide insights into the consequences of MIP dysfunc-
tion. Identification of this severe, early-onset condition ex-
pands the phenotypic spectrum associated with loss of
mitochondrial presequence protease function to include
cardiomyopathy and neurologic impairment.
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